Agenus Inc. - Common Stock (NQ:AGEN)

6.420 +0.240 (+3.88%)

Delayed Quote Updated: 4:00 PM EDT, Oct 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Agenus Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday ↗

June 30, 2022

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company announced it has terminated its previously announced at-the-market offering.

Via Benzinga

U.S. Stocks Turn Negative; 2U Shares Spike Higher ↗

June 29, 2022

U.S. stocks pared gains midway through trading, with all the three major indices turning lower on Wednesday.

Via Benzinga

Recap: Agenus Q1 Earnings ↗

May 10, 2022

Agenus (NASDAQ:AGEN) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Recap: Agenus Q4 Earnings ↗

March 01, 2022

Agenus (NASDAQ:AGEN) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings Agenus...

Via Benzinga

Earnings Scheduled For March 1, 2022 ↗

March 01, 2022

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...

Via Benzinga

Why Is Allena Pharmaceuticals Jumping By 207%? 45 Stocks Moving In Wednesday's Mid-Day Session ↗

June 29, 2022

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 207% to $0.3650 after the company announced it has terminated its previously announced at-the-market offering.

Via Benzinga

Agenus Touts 'Unprecedented Activity' For Botensilimab/Balstilimab Combo In Colorectal Cancer ↗

June 29, 2022

Via Benzinga

Agenus's Return On Capital Employed Insights ↗

June 08, 2022

According to Benzinga Pro data, during Q1, Agenus (NASDAQ:AGEN) posted sales of $25.94 million. Earnings were up 25.15%, but Agenus still reported an overall loss of $50.60 million.

Via Benzinga

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗

May 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Looking Into Agenus's Return On Capital Employed ↗

March 03, 2022

Benzinga Pro data, Agenus (NASDAQ:AGEN) reported Q4 sales of $20.26 million. Earnings fell to a loss of $67.61 million, resulting in a 138.14% decrease from last quarter. Agenus...

Via Benzinga

68 Biggest Movers From Yesterday ↗

March 03, 2022

Gainers ECMOHO Limited (NASDAQ: MOHO) climbed 56.7% to close at $0.3650 on Wednesday after jumping 10% on Tuesday. Imperial Petroleum Inc. (NASDAQ: IMPP) shares jumped 39.2% to...

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

February 04, 2022

On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap...

Via Benzinga

41 Stocks Moving In Wednesday's Mid-Day Session ↗

March 02, 2022

Gainers ECMOHO Limited (NASDAQ: MOHO) jumped 67% to $0.3890 after jumping 10% on Tuesday. Nordstrom, Inc. (NYSE: JWN) shares jumped 38.7% to $27.11 after the company reported...

Via Benzinga

Agenus inc (AGEN) Q3 2021 Earnings Call Transcript ↗

November 12, 2021

AGEN earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Agenus Posts Early Data For CTLA-4 Drug Candidate Across Tumor Types ↗

November 12, 2021

In a Phase I study across nine tumor types, Agenus Inc’s (NASDAQ: AGEN) CTLA-4 drug AGN1181 posted one complete response and three partial responses (...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2021 ↗

December 16, 2021

Upgrades According to B of A Securities, the prior rating for Generac Holdings Inc (NYSE:

Via Benzinga

Why Agenus Was Rising High on Tuesday ↗

November 09, 2021

The biotech delivers better-than-expected Q3 results.

Via The Motley Fool

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗

November 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...

Via Benzinga

55 Biggest Movers From Friday ↗

October 25, 2021

Gainers Phunware, Inc. (NASDAQ: PHUN) shares jumped 471.2% to close at $8.74 on Friday. Phunware shares jumped over 45% on Thursday, possibly in sympathy with Digital World...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 22, 2021

Gainers Progenity (NASDAQ:PROG) stock increased by 18.48% to $2.96 during Friday's regular session. Progenity's stock is trading at a volume of 116.0 million...

Via Benzinga

35 Stocks Moving In Friday's Mid-Day Session ↗

October 22, 2021

Gainers Phunware, Inc. (NASDAQ: PHUN) rose 1099% to $18.35. Phunware shares jumped over 45% on Thursday, possibly in sympathy with Digital World Acquisition as traders circulated...

Via Benzinga

Here's Why Agenus Stock Is Getting Hammered Today ↗

October 22, 2021

The company's experimental anti-PD1 drug hit a wall.

Via The Motley Fool

Agenus' Combo Therapy Trial Shows Higher Responses In Cervical Cancer ↗

September 17, 2021

Agenus Inc (NASDAQ: AGEN) presented final results from the Bal/Zal combination study at the European Society for Medical Oncology (ESMO21) Virtual Conference 2021...

Via Benzinga

The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug ↗

August 25, 2021

ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Agenus Inc. (NASDAQ: AGEN)...

Via Benzinga

The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold ↗

September 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (...

Via Benzinga

Why Agenus Fell by Over 4% on Monday ↗

August 09, 2021

Investors were spooked by some ugly numbers in the company's latest earnings report.

Via The Motley Fool

The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical ↗

August 31, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...

Via Benzinga

The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration ↗

August 27, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...

Via Benzinga

Topics Intellectual Property

The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal ↗

August 24, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 23) AbbVie Inc. (NYSE: ABBV) (...

Via Benzinga

Stocks That Hit 52-Week Highs On Monday ↗

August 16, 2021

Before 10 a.m. ET on Monday, 71 companies hit new 52-week highs. Highlights: Apple (NASDAQ:AAPL) was the largest firm on a market cap basis to set a new 52-week...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.